Plasma cholinesterase variants and the anaesthetist

Anaesthesia

Volumn 35, Issue 2, 1980, Pages 174-197

  WHITTAKER, MARY ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

Enzymes; Genetic factors; Hyperthermia; Nenromuscular relaxants; plasma cholinesterase; Pregnancy; suxamethonium

Indexed keywords

CHOLINESTERASE; SUXAMETHONIUM;

ANESTHESIA COMPLICATION; BLOOD AND HEMOPOIETIC SYSTEM; GENETICS; HEREDITY; PREGNANCY; REVIEW;

ADULT; ANESTHESIA; APNEA; CHOLINESTERASES; FEMALE; GENE FREQUENCY; GENES; GENOTYPE; HUMAN; INFANT, NEWBORN; MALE; MALIGNANT HYPERTHERMIA; PREGNANCY; SUCCINYLCHOLINE; VARIATION (GENETICS);

EID: 0018827671     PISSN: 00032409     EISSN: 13652044     Source Type: Journal    
DOI: 10.1111/j.1365-2044.1980.tb03800.x     Document Type: Article

References (264)

1. Regeneration rates of serum cholinesterase in normal individuals and in patients with liver damage
2. Serum cholinesterase activity in the normal individual and in people with liver disease
3. Enzyme‐Diagnostik fur den praktischen Arzt. 1. Serum Cholinesterase
4. Über die Fähigkeit der geschädigten Leber, Serumcholinesterase zu bilden
5. Comparative studies on cholinesterase activity in serum and liver cells
6. The relationship between serum choline esterase and serum albumin
7. Die Korrelation zwischen dem Albumingehalt und der Cholinesteraseaktivit Acta t des Blutserums und ihre Beurteilung bei Albumin‐verlust
8. Zur Methodik und klinischen Bedentung der Cholinesterasebestim‐mung im Serum
9. Das Verhalten der Leber‐funktion im postoperativen Schock
10. Über einen Fall von kompletter Analbuminaemie ohne wesentliche klinische Krankheitszeiehen
11. Serum cholinesterase in analbuminemia
12. Cholinesterase in plasma: first reported absence in the Bantu; half life determination
13. Plasma esterase activity in patients with liver disease and the nephrotic syndrome
14. Serum‐Cholinesterase und Leber‐Erkrankungen
15. On distribution and inheritance of atypical forms of human serum cholinesterase as indicated by dibucaine numbers
16. Differential inhibition of human serum cholinesterase with fluoride: recognition of two new phenotypes
17. Genetic aspects of succinylcholine sensitivity
18. Serum cholinesterase activity during pregnancy, labor and the puerperium
19. Serum cholinesterase deficiency. II, Pregnancy
20. Serum pseudocholinesterase, pregnancy and suxamethonium
21. The response of infants and children to muscle relaxants
22. Plasma cholinesterase activity in newborns and infants
23. The serum cholinesterase in jaundice and diseases of the liver
24. Anaesthesia in operations for the relief of portal hypertension
25. Abnormal response to suxamethonium in polyarteritis nodosa
26. Choline‐esterase activity of human sera with special reference to hyperthyroidism
27. A new test for the presumptive diagnosis of neoplastic disease. Further investigations of cholinesterase in plasma, whole blood and blood cells on cancer of the lung, extrapulmonary tumors and tuberculosis
28. Choline‐esterase activity of normal and pathological human sera
29. Procaine esterase activity in human blood serum; a new test for toxic goiter
30. Studies of cholinesterase activity. V, Serum cholinesterase in patients with carcinoma
31. Modifications de l'activité de la cholinesté rase sérique dans le diagnostic différentiel des processus néoplastiques
32. Cholinésterase serique et acetylcholinesterase globulaire dans 89 cas de cancer
33. Serum cholinesterase in some pathological conditions
34. Cholinesterase activity in patients with rheumatoid arthritis
35. Observations on erythrocyte and plasma cholinesterase activity in dyscrasias of the blood
36. Suxamethonium sensitivity in health and disease. A clinical evaluation of pseudocholinesterase levels
37. Serum cholinesterase deficiency in renal failure
38. The relation of oedema to serum protein and pseudocholinesterase levels in the malnorished infant
39. Les cholinestérases (érythrocytaire et plasmatique) dans les anémies rénales. Action du traitement par epuration extra‐rénale
40. Serum cholinesterases. In:
41. Liver choline‐esterase in malnourished infants
42. Pseudocholinesterase activity as a guide to prognosis in malnutrition
43. Pseudocholinesterase activity in thyroid disease
44. Prolonged apnea following succinylcholine in cancer patients receiving AB‐132
45. The effect of a series of anti‐cancer drugs on plasma cholinesterase activity
46. Low serum pseudocholinesterase levels complicating treatment with phenelzine
47. Serum protein and cholinesterase changes in association with contraceptive pills
48. Depressed levels of serum‐pseudocholinesterase with ecothiophate iodide eyedrops
49. Blood cholinesterase activity of glaucoma patients treated with phospholine iodide
50. Experimental studies of the breakdown of epontol: determination of propanidid in human serum
51. The interaction of human cholinesterases with anticholinesterases used in the therapy of myasthenia gravis
52. In vitro effect of chlorpromazine on human cholinesterases
53. The inhibition of cholinesterases by pancuronium
54. Zur Cholinesterase—Hemmung durch Pancuronium
55. Blood cholinesterase levels in workers exposed to organo‐phosphorus insecticides
56. Danger of suxamethonium and endotracheal intubation in anaesthesia for burns
57. The use of muscle relaxants in burnt children
58. Serum cholinesterase activity in burned patients. I, Biochemical findings
59. Serum cholinesterase activity in burned patients. II, Anaesthesia, suxamethonium and hyperkalaemia
60. Cytotoxic drugs in bronchial carcinoma
61. Qualitative and quantitative defects of pseudocholinesterase activity
62. Cyclophosphamide, cholinesterase and anaesthesia
63. Changes in blood composition before and after dialysis with the Kolff twin coil kidney
64. Activity of blood serum cholinesterase and catalase as an index of the cause of typhus abdominalis
65. Sur les variations de l'activité pseudocholinestérase plasmatique au cours de I évolution du tétanos
66. Effect of vitamin A on cholinesterase activity in normal children and in children with protein‐calorie malnutrition
67. Importance of epinephrine‐like substances and cholinesterase activity in the pathogenesis of the epileptic syndrome
68. Genetical studies on a new variant of serum cholinesterase detected by electrophoresis
69. Increased plasma cholinesterase activity and succinylcholine resistance: a genetic variant
70. A pseudocholinesterase variant (E Cynthiana) associated with elevated plasma enzyme activity
71. A relationship between body fat and plasma pseudocholinesterase
72. Pseudocholinesterase in obese and hyperlipemic subjects
73. La cholinestérase sérique dans les maladies thyroidiennes
74. Untersuchungen Über die Aktivität der Cholinesterase des Serums und Wirkung von intravenöser Novocainbehandlung auf Psoriatiker
75. Serum cholinesterase activity in essential hypertension
76. Action de la corticotrophine sur l'activité cholinestérasique sanguine chez des sujets normaux et chez des malades allergiques respiratoires
77. Serumpseudocholinesterase in depression with notable anxiety
78. Cholinesterase activity and mental disease: a literature review
79. The structure of the active surface of serum cholinesterase
80. The possible biological function of cholinesterase
81. Proposed physiological function for plasma cholinesterase
82. Distribution of cholinesterase in normal lymph nodes and its possible relation to the regulation of tissue size
83. Esterase histochemistry of reticulo‐endothelial cells in the reticulo‐endothelial system and atherosclerosis
84. Cholinesterase activity in the Harderian gland of Anas domesticus
85. Cholinesterase activity of human plasma after intramuscular diisopropyl fluorphosphonate (DFP)
86. Half‐life of human serum cholinesterase following blood transfusion
87. Alkylphosphatintoxikation. Kasuistik einer schweren Vergiftung und Anwendung eines gerinigten menschlichen Cholinester‐asepräparats
88. Eine Sippe mit vollständiger Serum‐cholinesterasedefizienz
89. Suxamethonium apnoea terminated with commercial serum‐cholinesterase
90. Serum cholinesterase. Effect on the action of suxamethonium following administration to a patient with cholinesterase deficiency
91. Pseudocholinesterase activity of human whole blood, bank blood and blood protein solutions
92. The clinical stability of serum cholinesterase activity
93. Blood cholinesterase levels and range of personal variation in a healthy adult population
94. Concerning the question of individual constancy and individual specificity of three serum enzyme activities (serum cholinesterase EC.3. 1. 1. 8, ceruloplasmin EC. 1. 10. 3. 2 and alkaline phosphatase EC. 3. 1. 3. 1.)
95. Stability of pseudocholinesterase in stored blood
96. Measurement of blood cholinesterase
97. Stability of cholinesterase in frozen plasma
98. Die Bestimmung der Serumcholinesterase an der Leiche
99. Serum cholinesterase in health and disease
100. Some statistical data on atypical cholinesterase of human serum
101. The relation of sex, age, smoking status, birth rank and parental ages to pseudocholinesterase activity and phenotypes in a sample of Australian Caucasian adults
102. Influence of age, sex and oral contraceptives on human blood cholinesterase activity
103. Serum cholinesterase levels in families and twins
104. Les variations physiologiques de l'activité cholinestérasique du plasma chez l homme
105. Serum cholinesterase values in childhood in health and disease
106. Pseudocholinesterase in early infancy
107. Plasma cholinesterase activity in the newborn infant
108. The cholinesterase activity of the serum of newborn animals and of colostrum
109. Cholinesterase activities in the serum of healthy British children
110. Cholinesterase‐ und Transaminasen‐Aktivität im Serum von Kindern (3 bis 6 Jahre alt)
111. The hydrolysis of succinylcholine by cholinesterase
112. Hydrolysis of suxamethonium by different types of plasma
113. Hydrolysis of suxamethonium by plasma from subjects responding to the drug with prolonged apnoea, and by plasma from their relatives
114. Hydrolysis of succinyldicholine by pseudocholinesterase at low concentrations
115. The distribution destruction and elimination of muscle relaxants
116. Neuromuscular effects of suxamethonium in man
117. The hydrolysis of suxamethonium in human blood
118. 14C‐succinyl‐monocholine during controlled conditions
119. Beitrag zur Kenntnis der Succinylcholinspaltung und deren möglicher Zusammenhang mit atypischen Serumesterasen
120. Die Cholinesterasen des menschlichen Serums unter besonderer Berucksichtigung neu‐ester Ergebnisse
121. Variation in the cholinesterase‐inhibiting effect of succinylcholine
122. Cholinesterase types
123. A method for the detection of atypical forms of human serum cholinesterase: determination of dibucaine numbers
124. Prolonged apnoea following injection of succinyldicholine
125. The familial incidence of low pseudocholinesterase level
126. The familial incidence of low pseudocholinesterase level
127. The pseudocholinesterase variants. Esterase levels and dibucaine numbers in families selected through suxamethonium sensitive individuals
128. A “silent” pseudocholinesterase gene
129. Suxamethonium in the absence of pseudocholinesterase
130. Hereditary deficiency of pseudocholinesterase in Eskimos
131. Plasma cholinesterase variants—an unexpectedly high incidence of the silent allele
132. Heterogeneity in the silent gene phenotype of pseudocholinesterase of human serum
133. Silent cholinesterase gene: variations in the properties of serum enzyme in apparent homozygotes
134. Further variation of the “silent” cholinesterase gene
135. A third type of serum cholinesterase deficiency in Eskimos
136. Complete pseudocholinesterase deficiency: genetic and immunologic characterization
137. Biochemische Untersuchungen zur Frage der Existenz eines “silent Gene” im Polymorphismus der Pseudocholinesterasen
138. Evidence for the different “silent genes” in the human serum pseudocholinesterase polymorphism
139. Inheritance of two types of deficiency of human serum cholinesterase
140. The “silent” gene for serum cholinesterase
141. The serum cholinesterase variants. A study of twenty‐two families selected by the “intermediate” phenotype
142. A new pseudocholinesterase phenotype
143. An additional pseudocholinesterase phenotype occurring in suxamethonium apnoea
144. Differential inhibition of human serum cholinesterase with n‐butyl alcohol: recognition of new phenotypes
145. New allele at cholinesterase locus 1
146. 1J, A quantitative variant at cholinesterase locus 1: immunological evidence
147. 1k, another quantitative variant at cholinesterase locus 1
148. Evidence for mutation being the source for the abnormal gene for plasma cholinesterase
149. A pseudocholinesterase variant in human tissues
150. Serum cholinesterase anenzymia. Report of a case confirmed by enzyme‐histochemical examination of liver‐biopsy specimen
151. 1) and transferrin (Tf) loci to chromosome 1 in man
152. Human cholinesterase (pseudocholinesterase): genetic variants and their recognition
153. Incidence of suxamethonium apnoea in patients undergoing E.C.T
154. A Danish Cholinesterase Research Unit
155. Prolonged apnoea after suxamethonium: an analysis of the first 225 cases reported to the Danish Cholinesterase Research Unit
156. Lecture to Magill Department of Anaesthetics, Westminster Hospital
157. Hypoventilation in a newborn following administration of succinylcholine to the mother: a case report
158. Response of the newborn to succinylcholine injection in homozygotic atypical mothers
159. Hydrolysis of succinylcholine by placental homogenates
160. The response of newborns to succinylcholine and d‐tubocurarine
161. Pharmacokinetics of succinylcholine in newborns
162. The placental transmission of succinylcholine
163. Investigation of placental thresholds to succinylcholine
164. Nature of placental cholinesterase
165. Studies on the levels and nature of cholinesterase in human and mouse placenta
166. Cholinésterases (acétyl et pseudo‐cholinestérase) dans le liquide amniotique humaine
167. Plasma acetyl‐cholinesterase activity
168. Studies of cholinesterase activity. IV, Liver function in pregnancy: value of certain standard liver function tests in normal pregnancy
169. of enzyme activities during normal pregnancy
170. Human serum cholinesterase: variations during pregnancy and postpartum
171. La colinesterasi serica in ostetrica: valori della C.S. nella gravidanza normale (Serum cholinesterase in obstetrics: values in normal pregnancies)
172. Studies in the cholinesterase‐hormone relationship
173. Potentiation of muscle relaxants by magnesium sulfate therapy in toxemia of pregnancy
174. Suxamethonium apnoea: a study of 18 cases
175. Correlation of plasma cholinesterase activity and duration of action of succinylcholine during pregnancy
176. Changes in plasma cholinesterase isoenzymes due to oral contraceptives
177. Interactions of steroids and serum cholinesterase
178. Substrate competition between procaine and succinylcholine for plasma cholinesterase
179. Potentiation of the neuromuscular effect of succinylcholine by hexafluorenium
180. Potentiation of the neuromuscular effect of succinylcholine by tetrahydroamino‐acridine
181. The muscle relaxants and their antagonists
182. The neuromuscular interaction of propanidid with suxamethonium and tubocurarine
183. Unusual urinary compound in patients homozygous for herditary atypical serum cholinesterase
184. Atypical cholinesterase in a patient with myasthenia gravis
185. The effect of pretreatment with non‐depolarising muscle relaxants on the neuro
186. Modification of the action of pancuronium by succinylcholine and halothane
187. The placental transfer of pancuronium bromide
188. Effect of pseudo‐cholinesterase level on the action of succinylcholine in man
189. The interrelationship of succinylcholine and the blood cholinesterases during anesthesia
190. Pharmakogenetische Reaktion auf Succinyldicholin: Therapie der verlängerten Apnoe
191. Suxamethonium sensitivity
192. Applikation von Serumcholinesterase bei verlängerter Apnoe nach Succinylbischolin
193. The use of serum cholinesterase in succinylcholine apnoea
194. Effect of plasma‐cholinesterase preparation on the phase II block of succinylcholine chloride in man
195. The activity of various esterase inhibitors towards atypical human serum cholinesterase
196. Differential inhibition of “usual” and “atypical” serum cholinesterase by NaCl and NaF
197. The pseudocholinesterase variants. Differentiation by means of sodium chloride
198. A rapid screening test for atypical serum‐cholinesterase
199. Mesure qualitative et quantitative de l'activité des pseudocholinestérases
200. Urea inhibition of human pseudocholinesterase
201. The inhibition of serum cholinesterase by urea
202. The effect of some hypnotic and analgesic drugs on cholinesterase activity
203. Procedure for detecting atypical serum cholinesterase using o‐nitrophenylbutyrate as substrate
204. Differentiation of serum scholinesterase variants by succinyldicholine inhibition
205. Succinylcholine number. An improved qualitative test for plasma cholinesterase
206. Rapid screening method for the common atypical pseudocholinesterase variant
207. Value of butyrylthicholine assay for identification of cholinesterase variants
208. The serum cholinesterase variants. Differentiation by means of formaldehyde
209. The effect in vitro of thyroxine, glucagon, thyrotrophin and antithyroid drugs on “usual” and “atypical” human plasma cholinesterase
210. The pseudocholinesterase variants. Differentiation by means of alkyl alcohols
211. The action of normal and atypical cholinesterase of human serum upon a series of esters of choline
212. Properties of “usual” and “atypical” serum cholinesterase using o‐nitro‐phenyl butyrate as substrate
213. (1970) Spektrophotometrische Bestimmungsmethode für Serumcholinesterase (EC 3. 1. 1. 8)—Varianten mit Succinylbischolin als Substrat
214. A note on suxamethonium sensitivity and serum cholinesterase variants
215. Improved method for the differentiation of cholinesterase variants
216. Scope and limitations of proprionylthiocholine in the characterization of cholinesterase variants
217. Succinyldithiocholine: a new substrate for serum cholinesterase (EC 3. 1. 1. 8). Communication to the 8th International congress of clinical chemistry, Copenhagen, 1972
218. Serum cholinesterase variants: examination of several differential inhibitors, salts and buffers used to measure enzyme activity
219. A manual and automated procedure for measuring serum cholinesterase activity and identifying enzyme variants
220. Identification of serum cholinesterase fluoride variants by differential inhibition in tris and phosphate buffers
221. A source of error in the determination of inhibitor constants of serum cholinesterase
222. Estimation of plasma cholinesterase activity and the use of inhibitors for the determination of phenotypes
223. Use of a programmable calculator in processing and interpreting serum cholinesterase phenotypes
224. Detection of patients with low serum cholinesterase activity; inadequacy of “Acholest” method
225. The frequency of the fluoride resistant gene in a population of British students
226. Contribution of hereditary factors to the response to drugs
227. Initial experiences with the Cholinesterase Research Unit
228. New drugs for depression
229. The relation between dose of succinylcholine and duration of apnea in man
230. The plasma cholinesterase variants in mentally ill patients
231. Serum esterase in mongolism
232. Plasma cholinesterase polymorphism in Down's syndrome
233. 1 phenotypes in Down's syndrome and mental retardation
234. 2 loci
235. Qualitative and quantitative defects of pseudocholinesterase activity
236. Potentiation of succinylcholine neuromuscular blockade by lithium carbonate
237. Plasma cholinesterase variants in patients having lithium therapy
238. Possible mechanisms of action of lithium salts: approaches and perspectives
239. Lithium: an anaesthetic risk
240. Lithium in psychiatric therapy and prophylaxis
241. Serum atypical pseudocholinesterase and genetic factors in leprosy
242. Susceptibility to leprosy and serum atypical pseudocholinesterase
243. A note on atypical serum cholinesterase and gentic factors in leprosy
244. Serum cholinesterase variants in African leprosy patients resident in Rhodesia
245. Dapsone acetylation and the treatment of leprosy
246. Recent advances in malignant hyperthermia
247. Plasma cholinesterase and malignant hyperthermia
248. Plasma cholinesterase and malignant hyperpyrexia
249. Hereditary aspects of malignant hyperthermia
250. Malignant hyperpyrexia
251. Multi‐factorial inheritance of malignant hyperpyrexia susceptibility (MHS)
252. Aetiology of prolonged apnoea after suxamethonium
253. Succinyldicholin‐Empfindlichkeit als Folge bedingter Serumcholinesterasevarianten
254. A study of the pseudocholinesterase in 78 cases of apnoea following suxamethonium